drugset
drugset / Trial / NCT06190691

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691 ↗

Phase 1 Completed 36 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.

Timeline

Start
2020-12-18
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral

Indications

liver disorder